These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28025724)

  • 41. Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects.
    Kozin SA; Barykin EP; Mitkevich VA; Makarov AA
    Biochemistry (Mosc); 2018 Sep; 83(9):1057-1067. PubMed ID: 30472944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy.
    Sengupta U; Nilson AN; Kayed R
    EBioMedicine; 2016 Apr; 6():42-49. PubMed ID: 27211547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.
    Whitehead A; Perdomo C; Pratt RD; Birks J; Wilcock GK; Evans JG
    Int J Geriatr Psychiatry; 2004 Jul; 19(7):624-33. PubMed ID: 15254918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis.
    Jeong SY; Suh CH; Shim WH; Lim JS; Lee JH; Kim SJ
    Neurology; 2022 Nov; 99(19):e2092-e2101. PubMed ID: 36038268
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment.
    Montoliu-Gaya L; Villegas S
    Expert Rev Mol Med; 2016 Jun; 18():e13. PubMed ID: 27357999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.
    Bowen RL; Perry G; Xiong C; Smith MA; Atwood CS
    J Alzheimers Dis; 2015; 44(2):549-60. PubMed ID: 25310993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.
    Liu J; Yang B; Ke J; Li W; Suen WC
    Drugs Aging; 2016 Oct; 33(10):685-697. PubMed ID: 27699633
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease.
    Richard E; den Brok MGHE; van Gool WA
    Alzheimers Dement; 2021 Jun; 17(6):1051-1055. PubMed ID: 34057297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
    Holmes C; Boche D; Wilkinson D; Yadegarfar G; Hopkins V; Bayer A; Jones RW; Bullock R; Love S; Neal JW; Zotova E; Nicoll JA
    Lancet; 2008 Jul; 372(9634):216-23. PubMed ID: 18640458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities.
    Bechten A; Wattjes MP; Purcell DD; Aliaga ES; Daams M; Brashear HR; Arrighi HM; Barkhof F
    J Neuroimaging; 2017 May; 27(3):318-325. PubMed ID: 28102639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Abdelazim K; Allam AA; Afifi B; Abdulazeem H; Elbehiry AI
    Neurol Sci; 2024 Aug; 45(8):3583-3597. PubMed ID: 38565747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Passive antiamyloid immunotherapy for Alzheimer's disease.
    Loureiro JC; Pais MV; Stella F; Radanovic M; Teixeira AL; Forlenza OV; de Souza LC
    Curr Opin Psychiatry; 2020 May; 33(3):284-291. PubMed ID: 32040044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.
    Martens RM; Bechten A; Ingala S; van Schijndel RA; Machado VB; de Jong MC; Sanchez E; Purcell D; Arrighi MH; Brashear RH; Wattjes MP; Barkhof F
    Eur Radiol; 2018 Mar; 28(3):1215-1226. PubMed ID: 28956123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
    Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
    J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel method of treating Alzheimer's disease.
    Chen V
    Lancet Neurol; 2005 Oct; 4(10):599. PubMed ID: 16208857
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy and safety of anti-amyloid-
    Mo JJ; Li JY; Yang Z; Liu Z; Feng JS
    Ann Clin Transl Neurol; 2017 Dec; 4(12):931-942. PubMed ID: 29296624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.
    Lacorte E; Ancidoni A; Zaccaria V; Remoli G; Tariciotti L; Bellomo G; Sciancalepore F; Corbo M; Lombardo FL; Bacigalupo I; Canevelli M; Piscopo P; Vanacore N
    J Alzheimers Dis; 2022; 87(1):101-129. PubMed ID: 35275549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy.
    DiFrancesco JC; Longoni M; Piazza F
    Front Neurol; 2015; 6():207. PubMed ID: 26441825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.